<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33549">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02669875</url>
  </required_header>
  <id_info>
    <org_study_id>STOPP</org_study_id>
    <nct_id>NCT02669875</nct_id>
  </id_info>
  <brief_title>Serelaxin To Lower Portal Pressure</brief_title>
  <acronym>STOPP</acronym>
  <official_title>Serelaxin To Lower Portal Pressure in Patients With Cirrhosis and Portal Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>NHS Lothian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Portal hypertension (an increase in blood pressure in the portal vein that carries the blood
      from the intestine and spleen to the liver) underlies most of the serious complications of
      liver cirrhosis. This randomised placebo controlled study in people with liver cirrhosis
      evaluates the acute effects serelaxin (RLX030) infusion on portal hypertension and liver
      blood flow.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will investigate the effects of the investigational drug serelaxin (a recombinant
      form of the peptide human relaxin-2) on portal hypertension in patients with liver
      cirrhosis. The investigators will measure portal pressure by hepatic venous pressure
      gradient (HVPG) and hepatic blood flow by indocyanine green (ICG) clearance to evaluate the
      potential benefits of the drug. In a recently completed small exploratory open-label phase 2
      study (EudraCT no. 201200023626, NCT01640964), Part B demonstrated that serelaxin can lower
      portal pressure.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in fasting hepatic venous pressure gradient (HVPG)</measure>
    <time_frame>Baseline, after 2 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting hepatic venous pressure gradient (HVPG)</measure>
    <time_frame>Baseline, after 1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting hepatic blood flow</measure>
    <time_frame>Baseline, after 2 hours</time_frame>
    <description>Measured from the concentration of indocyanine green (ICG) in the hepatic venous blood vs peripheral venous blood using the Fick Principle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in right atrial pressure</measure>
    <time_frame>Baseline, after 2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cardiac index</measure>
    <time_frame>Baseline, after 2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in systemic vascular resistance index</measure>
    <time_frame>Baseline, after 2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>4 weeks</time_frame>
    <description>Adverse events (AE) reporting will be summarized based on number of patients reported with abnormal laboratory values, clinically significant AE, serious adverse events or death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Hypertension, Portal</condition>
  <arm_group>
    <arm_group_label>Serelaxin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV infusion of serelaxin (RLX030) for 2 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV infusion of placebo (20mM sodium acetate pH5) matched to serelaxin for 2 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Serelaxin</intervention_name>
    <description>Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution</description>
    <arm_group_label>Serelaxin</arm_group_label>
    <other_name>RLX030</other_name>
    <other_name>Recombinant human relaxin-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo solution (20mM sodium acetate pH5) diluted in 5% v/v glucose solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female adult subjects over 18 years of age

          2. Able to provide written informed consent and able to understand and willing to comply
             with the requirements of the study

          3. Clinical imaging-diagnosed or biopsy-proven liver cirrhosis of any aetiology

          4. Evidence of portal hypertension either on imaging or previous endoscopy

          5. Patients with large/grade 3 varices as identified by endoscopy within 6 months of
             screening must be in an endoscopic band ligation programme at the time of study entry

          6. Suspected hepatic venous pressure gradient (HVPG) â‰¥10 mmHg at baseline

        Exclusion Criteria:

          1. Pregnancy or breast feeding

          2. Severe liver failure defined by one of the following: Prothrombin activity &lt;40%,
             Bilirubin &gt;5 mg/dL (85umol/L), hepatic encephalopathy &gt; grade I

          3. Presence of any non-controlled and clinically significant disease that could affect
             the study outcome or that would place the patient at undue risk

          4. Hepatocellular carcinoma

          5. Portal vein thrombosis

          6. Previous surgical shunt or TIPSS

          7. Current use of beta-blockers or nitrates, any other drug therapy known to have an
             influence on portal pressure (diuretics permitted provided patients have been on a
             stable dose for at least 30 days)

          8. History of drug or alcohol abuse within 1 month of enrolment

          9. Arterial hypotension (sitting Systolic Blood Pressure &lt;100 mmHg)

         10. Use of other investigational drugs within 5 half-lives of enrolment, or within 30
             days/until the expected pharmacodynamic effect has returned to baseline, whichever is
             longer

         11. Long QT syndrome

         12. Documented hypersensitivity to intravenous contrast agents and/or iodine

         13. Severe renal impairment (eGFR&lt;30)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Liver Unit, Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH164TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Fallowfield JA, Hayden AL, Snowdon VK, Aucott RL, Stutchfield BM, Mole DJ, Pellicoro A, Gordon-Walker TT, Henke A, Schrader J, Trivedi PJ, Princivalle M, Forbes SJ, Collins JE, Iredale JP. Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo. Hepatology. 2014 Apr;59(4):1492-504. doi: 10.1002/hep.26627. Epub 2014 Mar 3.</citation>
    <PMID>23873655</PMID>
  </reference>
  <reference>
    <citation>Kobalava Z, Villevalde S, Kotovskaya Y, Hinrichsen H, Petersen-Sylla M, Zaehringer A, Pang Y, Rajman I, Canadi J, Dahlke M, Lloyd P, Halabi A. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study. Br J Clin Pharmacol. 2015 Jun;79(6):937-45. doi: 10.1111/bcp.12572.</citation>
    <PMID>25511105</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>February 2, 2016</lastchanged_date>
  <firstreceived_date>January 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
